EP1996619A4 - Gpcrs as angiogenesis targets - Google Patents

Gpcrs as angiogenesis targets

Info

Publication number
EP1996619A4
EP1996619A4 EP07750916A EP07750916A EP1996619A4 EP 1996619 A4 EP1996619 A4 EP 1996619A4 EP 07750916 A EP07750916 A EP 07750916A EP 07750916 A EP07750916 A EP 07750916A EP 1996619 A4 EP1996619 A4 EP 1996619A4
Authority
EP
European Patent Office
Prior art keywords
gpcrs
angiogenesis targets
angiogenesis
targets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07750916A
Other languages
German (de)
French (fr)
Other versions
EP1996619A2 (en
Inventor
Tinchung Leung
Janet D Robishaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geisinger Clinic
Original Assignee
Geisinger Clinic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geisinger Clinic filed Critical Geisinger Clinic
Publication of EP1996619A2 publication Critical patent/EP1996619A2/en
Publication of EP1996619A4 publication Critical patent/EP1996619A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP07750916A 2006-02-14 2007-02-14 Gpcrs as angiogenesis targets Withdrawn EP1996619A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77299106P 2006-02-14 2006-02-14
PCT/US2007/004114 WO2007095353A2 (en) 2006-02-14 2007-02-14 Gpcrs as angiogenesis targets

Publications (2)

Publication Number Publication Date
EP1996619A2 EP1996619A2 (en) 2008-12-03
EP1996619A4 true EP1996619A4 (en) 2009-11-18

Family

ID=38372149

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07750916A Withdrawn EP1996619A4 (en) 2006-02-14 2007-02-14 Gpcrs as angiogenesis targets

Country Status (3)

Country Link
EP (1) EP1996619A4 (en)
JP (1) JP2009526861A (en)
WO (1) WO2007095353A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101756131B1 (en) 2014-09-26 2017-07-12 주식회사 바이로메드 Composition for Preventing or Treating Peripheral Artery Disease Using Hepatocyte Growth Factor and Stromal Cell Derived Factor 1 alpha
FR3077574B1 (en) 2018-02-07 2022-04-01 Commissariat Energie Atomique ANTIBODIES DIRECTED AGAINST ENDOTHELIN RECEPTOR SUBTYPE A AND THEIR USES.

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028258A1 (en) * 1996-01-30 1997-08-07 The National Institutes Of Health Cells expressing both human cd4 and cxcr4
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
WO2000052039A2 (en) * 1999-03-04 2000-09-08 Icos Corporation Lectomedin materials and methods
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
WO2002079492A2 (en) * 2001-02-14 2002-10-10 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2004075835A2 (en) * 2003-02-21 2004-09-10 Genentech Inc. Methods for the treatment of renal cell carcinoma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69317883T2 (en) * 1992-11-17 1998-11-12 Icos Corp., Bothell, Wash. New seven-transmembrane receptor V28

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028258A1 (en) * 1996-01-30 1997-08-07 The National Institutes Of Health Cells expressing both human cd4 and cxcr4
WO1999047158A2 (en) * 1998-03-13 1999-09-23 The University Of British Columbia Therapeutic chemokine receptor antagonists
US20020107195A1 (en) * 1998-07-21 2002-08-08 Smithkline Beecham Corporation Method for inducing chemotaxis in endothelial cells by administering stromal cell derived factor-1alpha
WO2000052039A2 (en) * 1999-03-04 2000-09-08 Icos Corporation Lectomedin materials and methods
WO2002079492A2 (en) * 2001-02-14 2002-10-10 Protein Design Labs, Inc. Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
WO2004075835A2 (en) * 2003-02-21 2004-09-10 Genentech Inc. Methods for the treatment of renal cell carcinoma

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BAGNATO ANNA; CIRILLI ALESSIA; SALANI DEBORA; SIMEONE PAOLA; MULLER ANTONIO; NICOTRA MARIA RITA; NATALI PIER GIORGIO; VENUTI ALDO: "Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.", CANCER RESEARCH 15 NOV 2002, vol. 62, no. 22, 15 November 2002 (2002-11-15), pages 6381 - 6384, XP002548798, ISSN: 0008-5472 *
HEIDEMANN JAN ET AL: "Mucosal angiogenesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells.", AMERICAN JOURNAL OF PHYSIOLOGY. GASTROINTESTINAL AND LIVER PHYSIOLOGY JUN 2004, vol. 286, no. 6, June 2004 (2004-06-01), pages G1059 - G1068, XP002548626, ISSN: 0193-1857 *
KAHN JOY ET AL: "Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation.", BLOOD 15 APR 2004, vol. 103, no. 8, 15 April 2004 (2004-04-15), pages 2942 - 2949, XP002548627, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
WO2007095353A3 (en) 2009-04-16
WO2007095353A2 (en) 2007-08-23
JP2009526861A (en) 2009-07-23
EP1996619A2 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
EP2051097A4 (en) Radar
IL195246A0 (en) Atomiser
EP2013341A4 (en) Disease-inducible promoters
GB0821585D0 (en) Bracket
IL180020A0 (en) Encryption -and decryption-enabled interfaces
GB0714011D0 (en) Radar aaparatus
ZA200810662B (en) Cold-pressed sputter targets
IL192799A0 (en) Substituted 4-phenylpiperidines
GB2437850B (en) Bracket
AU308858S (en) Bracket
ZA200903382B (en) Substituted 4-imidazoles
EP1996619A4 (en) Gpcrs as angiogenesis targets
GB0609979D0 (en) Target
EP2067777A4 (en) Oxepin derivative
GB2442217B (en) Gaiter
GB0625270D0 (en) Angiogenesis
GB2448674B (en) Sword targets
GB0601059D0 (en) Target
GB0612843D0 (en) Radar
GB0718790D0 (en) Anti-cancer target
GB0711602D0 (en) Anti-cancer target
GB0722839D0 (en) Target
GB2437733B (en) Bracket
HU0600663D0 (en) Compromise i
GB0700454D0 (en) Delay control

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080911

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

R17D Deferred search report published (corrected)

Effective date: 20090416

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 48/00 20060101ALI20090427BHEP

Ipc: C07H 21/02 20060101AFI20090427BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20091016

17Q First examination report despatched

Effective date: 20100125

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100805